UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase I study of the recombinant humanized anti-HER2 monoclonal antibody–MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2021-07, Vol.24 (4), p.913-925

2021

Volltextzugriff (PDF)

Reduced m6A modification predicts malignant phenotypes and augmented Wnt/PI3K‐Akt signaling in gastric cancer

Cancer medicine (Malden, MA), 2019-08, Vol.8 (10), p.4766-4781

2019

Volltextzugriff (PDF)

Predicting response to immunotherapy in gastric cancer via multi-dimensional analyses of the tumour immune microenvironment

Nature communications, 2022-08, Vol.13 (1), p.4851-4851, Article 4851

2022

Volltextzugriff (PDF)

Positive Status of Epstein-Barr Virus as a Biomarker for Gastric Cancer Immunotherapy: A Prospective Observational Study

Journal of immunotherapy (1997), 2020-05, Vol.43 (4), p.139-144

2020

Volltextzugriff (PDF)

Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer

BMC medicine, 2022-07, Vol.20 (1), p.1-15, Article 223

2022

Volltextzugriff (PDF)

Evolutionary expression of HER2 conferred by chromosome aneuploidy on circulating gastric cancer cells contributes to developing targeted and chemotherapeutic resistance

Clinical cancer research, 2018-11, Vol.24 (21), p.5261-5271

2018

Volltextzugriff (PDF)

Hepatoid adenocarcinoma of the stomach: a unique subgroup with distinct clinicopathological and molecular features

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2019-11, Vol.22 (6), p.1183-1192

2019

Volltextzugriff (PDF)

Hyperprogression after immunotherapy in patients with malignant tumors of digestive system

BMC cancer, 2019-07, Vol.19 (1), p.705-705, Article 705

2019

Volltextzugriff (PDF)

CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer

Journal of hematology and oncology, 2023-09, Vol.16 (1), p.1-102, Article 102

2023

Volltextzugriff (PDF)

Phase I study of intraperitoneal bevacizumab for treating refractory malignant ascites

Journal of international medical research, 2021-02, Vol.49 (2), p.300060520986664

2021

Volltextzugriff (PDF)

Association of Lymphocyte-to-Monocyte Ratio With Survival in Advanced Gastric Cancer Patients Treated With Immune Checkpoint Inhibitor

Frontiers in oncology, 2021-06, Vol.11, p.589022-589022

2021

Volltextzugriff (PDF)

Clinical study of ultrasound and microbubbles for enhancing chemotherapeutic sensitivity of malignant tumors in digestive system

Chinese journal of cancer research, 2018-10, Vol.30 (5), p.553-563

2018

Volltextzugriff (PDF)

Impact of 68Ga-NOTA-MAL-MZHER2 PET imaging in advanced gastric cancer patients and therapeutic response monitoring

European journal of nuclear medicine and molecular imaging, 2021, Vol.48 (1), p.161-175

2021

Volltextzugriff (PDF)

PTCH1 mutation promotes antitumor immunity and the response to immune checkpoint inhibitors in colorectal cancer patients

Cancer Immunology, Immunotherapy, 2022-01, Vol.71 (1), p.111-120

2022

Volltextzugriff (PDF)

From AVATAR Mice to Patients: RC48-ADC Exerted Promising Efficacy in Advanced Gastric Cancer With HER2 Expression

Frontiers in pharmacology, 2022-01, Vol.12, p.757994-757994

2022

Volltextzugriff (PDF)

Correction: Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer

BMC medicine, 2023-09, Vol.21 (1), p.1-369, Article 369

2023

Volltextzugriff (PDF)

Immune checkpoint inhibitor-induced colitis with endoscopic evaluation in Chinese cancer patients: a single-centre retrospective study

Frontiers in oncology, 2023-11, Vol.13, p.1285478-1285478

2023

Volltextzugriff (PDF)

Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers

Frontiers in immunology, 2022-09, Vol.13, p.987568-987568

2022

Volltextzugriff (PDF)

Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer

Journal for immunotherapy of cancer, 2020-08, Vol.8 (2), p.e000374

2020

Volltextzugriff (PDF)

Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial

Cancer science, 2016-04, Vol.107 (4), p.486-490

2016

Volltextzugriff (PDF)

A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer

NPJ precision oncology, 2021-05, Vol.5 (1), p.36-9, Article 36

2021

Volltextzugriff (PDF)

Germline HLA-B evolutionary divergence influences the efficacy of immune checkpoint blockade therapy in gastrointestinal cancer

Genome medicine, 2021-11, Vol.13 (1), p.175-15, Article 175

2021

Volltextzugriff (PDF)

Trastuzumab Combined with Irinotecan in Patients with HER2-Positive Metastatic Colorectal Cancer: A Phase II Single-Arm Study and Exploratory Biomarker Analysis

Cancer Research and Treatment, 2023, 55(2), , pp.626-635

2023

Volltextzugriff (PDF)

Aneuploidy of chromosome 8 in circulating tumor cells correlates with prognosis in patients with advanced gastric cancer

Chinese journal of cancer research, 2016-12, Vol.28 (6), p.579-588

2016

Volltextzugriff (PDF)

Hyperprogression of cutaneous T cell lymphoma after anti-PD-1 treatment

JCI insight, 2023-02, Vol.8 (4)

2023

Volltextzugriff (PDF)

1 – 25 von 206

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(187)
Mit Volltextzugriff
(181)

Publikationsform

Artikel
(203)
Tagungsberichte
(3)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Phase I study of the recombinant humanized anti-HER2 monoclonal antibody–MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors

Reduced m6A modification predicts malignant phenotypes and augmented Wnt/PI3K‐Akt signaling in gastric cancer

Predicting response to immunotherapy in gastric cancer via multi-dimensional analyses of the tumour immune microenvironment

Positive Status of Epstein-Barr Virus as a Biomarker for Gastric Cancer Immunotherapy: A Prospective Observational Study

Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer

Evolutionary expression of HER2 conferred by chromosome aneuploidy on circulating gastric cancer cells contributes to developing targeted and chemotherapeutic resistance

Hepatoid adenocarcinoma of the stomach: a unique subgroup with distinct clinicopathological and molecular features

Hyperprogression after immunotherapy in patients with malignant tumors of digestive system

CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer

Phase I study of intraperitoneal bevacizumab for treating refractory malignant ascites

Association of Lymphocyte-to-Monocyte Ratio With Survival in Advanced Gastric Cancer Patients Treated With Immune Checkpoint Inhibitor

Clinical study of ultrasound and microbubbles for enhancing chemotherapeutic sensitivity of malignant tumors in digestive system

Impact of 68Ga-NOTA-MAL-MZHER2 PET imaging in advanced gastric cancer patients and therapeutic response monitoring

PTCH1 mutation promotes antitumor immunity and the response to immune checkpoint inhibitors in colorectal cancer patients

From AVATAR Mice to Patients: RC48-ADC Exerted Promising Efficacy in Advanced Gastric Cancer With HER2 Expression

Correction: Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer

Immune checkpoint inhibitor-induced colitis with endoscopic evaluation in Chinese cancer patients: a single-centre retrospective study

Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers

Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer

Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial

A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer

Germline HLA-B evolutionary divergence influences the efficacy of immune checkpoint blockade therapy in gastrointestinal cancer

Trastuzumab Combined with Irinotecan in Patients with HER2-Positive Metastatic Colorectal Cancer: A Phase II Single-Arm Study and Exploratory Biomarker Analysis

Aneuploidy of chromosome 8 in circulating tumor cells correlates with prognosis in patients with advanced gastric cancer

Hyperprogression of cutaneous T cell lymphoma after anti-PD-1 treatment

Suchergebnisse filtern